Added Benefit For Orphans Is ‘Fictitious’ Says German HTA Body
Executive Summary
Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.
You may also be interested in...
German HTA Body To Have New Director
Thomas Kaiser is to become the new director of the German health technology assessment institute, IQWiG.
Alnylam's Amvuttra Tests Faster HTA In England, Wins Praise in Germany For Full Assessment
Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.
Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period
Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.